Pfizer Offers 6% Dividend Yield and Growth Potential Beyond Its COVID-19 Portfolio
Pfizer (NYSE: PFE) is transitioning beyond its reliance on pandemic-related products, such as its COVID-19 vaccine, to focus on broader growth opportunities in areas like oncology. In the second quarter of this year, revenue from non-COVID launched and acquired products increased by 18% compared to last year, prompting management to raise full-year guidance midyear. The company is expanding into cancer treatments through acquisitions, partnerships, and research programs that include antibody-drug conjugates and bispecific antibodies. These innovations aim to improve existing therapies and develop new ones for difficult-to-treat cancers like breast, prostate, bladder, and lung cancers. Additionally, Pfizer has partnered with Innovent Biologics on 12 early-stage cancer medicine programs. While the company's pipeline is still developing, investors are currently rewarded through a robust dividend yield of approximately 6%. This high yield provides income while long-term growth potential emerges from its expanding portfolio and research initiatives.
Tickers: $PFE